BLB(SZ:002286) Zheng Quan Shi Bao Wang·2025-11-14 09:09Core Insights - The recent approval of infant formula products with upgraded formulations, particularly focusing on the addition of 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT), indicates a significant shift in the market for infant nutrition products in China [1][2]. Regulatory Developments - The approval process for Human Milk Oligosaccharides (HMOs) began in 2016, with 2023 marking a milestone year as the National Health Commission officially approved 2'-FL and LNnT as food nutrition fortifiers for infant formula and other specialized products [2][3]. - By October 2023, nearly 20 HMO products had received approval, with multiple companies claiming the ability to supply HMO products [2]. Market Dynamics - The approval of HMO formulations by leading dairy companies such as Yili, Feihe, and Junlebao signifies the establishment of a complete industrial cycle from raw material approval to product launch, transitioning the industry into a phase of large-scale application [3]. - The market for HMOs, previously dominated by foreign companies, is experiencing a shift due to breakthroughs in domestic synthetic biology, significantly reducing production costs and enabling local companies to compete effectively [4]. Technological Advancements - Domestic advancements in synthetic biology have led to a substantial decrease in the production cost of 2'-FL, with prices dropping below 500,000 yuan per ton, making it feasible for local dairy companies to upgrade their formulas [4]. - Companies like Baolingbao have developed proprietary strains and enzyme immobilization processes, achieving international standards in purity and production capacity [4]. Customer and Market Strategy - Baolingbao's extensive customer base in the infant formula sector positions it well to capitalize on the growing demand for HMO products, with major brands already preparing to launch HMO-enhanced products [5]. - The company is diversifying its product offerings beyond infant formula to include HMO and other prebiotic products, catering to a broader range of dairy and beverage clients [5]. Market Projections - According to QYResearch, the global HMO market is projected to reach $704 million in 2024 and exceed $3.21 billion by 2031, with a CAGR of 24.6% from 2025 to 2031, indicating a much higher growth rate in the Chinese market compared to the global average [6].